3 Biotech Stocks with Oncoming Catalysts

For these three companies, trial results will make a big difference.

Jun 13, 2014 at 5:30PM

For companies that are developing new and innovative treatments, few events can move the share price as much as the results of clinical trials. For clinical-stage biotechs, trial results are a huge indicator of potential future success. With this in mind, there are a variety of companies that are expecting key clinical trial results relatively soon. Now, biotech stocks aren't for the faint of heart -- each of these three companies is burning through cash, and so investors should exercise appropriate caution when considering 

Xoma Corporation (NASDAQ:XOMA) is expecting clinical trial results for its drug Gevokizumab. Gevokizumab is being developed in a variety of indications, however, the trial that they are expecting results for is in a phase 3 trial for Behcet's disease. The results for the phase 3 trial called EYEGUARD-B are expected before the end of June.

This trial is very important for Xoma, as its success would validate Gevokizumab's mechanism of action and also bring this flagship drug a step closer to commercialization. Gevokizumab is being tested in a variety of indications including non-infectious uveitis as well as pyoderma gangrenosum, for which the drug recently obtained Orphan Drug designation.

If approved by the FDA, Xoma's partner Servier would handle most of the marketing for the drug, which would provide revenue for Xoma essentially without cost (although Xoma has commercialization rights in the U.S. and Japan for all indications aside from cardiovascular disease and diabetes). With a net loss of $4.7 million reported for the first quarter of 2014 (and excluding the revaluation of warrant liabilities, that loss would have ballooned to $24.7), Xoma needs the money. The company's cash position ($94 million in cash and $60 million in operating cash flow burned over the past 12 months) highlights the importance of this drug getting to market.

GW Pharmaceuticals (NASDAQ:GWPH) is expecting results later this year from a phase 2a clinical trial for its drug GWP42003 in patients with ulcerative colitis. GW is also testing the drug for a schizophrenia indication in another 2a trial, with data expected in late 2015.

Sativex, which is GW Pharma's flagship drug, is approved in a variety of countries for MS Spasticity, and is is also expecting data from a phase 3 clinical trial for Sativex. This trial is very important to GW as it would provide the basis for a New Drug Application with the FDA and would help to get Sativex on the market in the U.S. Sativex is already approved in many countries for the treatment of MS Spacity (notably not the United States), so approval for Sativex would help to get the drug on the market with the potential to later expand Sativex's label within the United States. With a net loss of $8.7 million last quarter, GW needs more approvals and revenue -- and Sativex's phase 3 may be its best opportunity.

Opko Health (NYSE:OPK) is expecting clinical trial results for its drug Rayaldee for vitamin D insufficiency which is the subject of several phase 3 trials. Top-line data for the trials (which test the drug's efficacy in treating secondary hyperparathyroidism) are expected in mid-2014 with a potential NDA filed in early 2015.

Opko appears to be planning on launching Rayaldee by itself, and has been busy securing a supply chain for the drug. Opko needs sales to turn toward profitability, and given that the company burned through over $72 million in the trailing-12 months and has about $156 million in cash reserves, that turn is needed.

With this in mind, Opko's drug Rolapitant is on track for a mid-2014 NDA filing, so this drug should also help to bridge the gap in terms of Opko's operating losses.

Final thoughts
Each of the drugs mentioned in this article have the potential to substantially impact the future at each company. Investors should watch closely for hints of success in these trials, and should be able to adjust their investment strategies accordingly. It's also important to note that success in the lab doesn't necessarily translate to marketing success, so even if these drugs make it past the FDA, there will be additional challenges ahead.

Leaked: A huge small-cap opportunity
This smart device –kept secret until now – could mark a new revolution in smart tech (with big implications for health care). It's a gigantic market opportunity -- ABI Research predicts 485 million of its type will be sold per year. To learn about the small-cap stock making this device possible – the stock that could mint millionaires left and right when its full market potential is realized – click here.

Alexander Maxwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information